schliessen

Filtern

 

Bibliotheken

Thyroid cancer

Summary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the stand... Full description

Journal Title: The Lancet (British edition) 2016, Vol.388 (10061), p.2783-2795
Main Author: Cabanillas, Maria E, Dr
Other Authors: McFadden, David G, MD , Durante, Cosimo, MD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/27240885
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1826692040
title: Thyroid cancer
format: Article
creator:
  • Cabanillas, Maria E, Dr
  • McFadden, David G, MD
  • Durante, Cosimo, MD
subjects:
  • Carcinoma, Neuroendocrine - diagnosis
  • Carcinoma, Neuroendocrine - diagnostic imaging
  • Carcinoma, Neuroendocrine - surgery
  • Clinical trials
  • Development and progression
  • Diagnosis, Differential
  • Disease-Free Survival
  • Humans
  • Internal Medicine
  • Iodine
  • Kinases
  • Metastasis
  • Mutation
  • Severity of Illness Index
  • Thyroid cancer
  • Thyroid Neoplasms - diagnosis
  • Thyroid Neoplasms - diagnostic imaging
  • Thyroid Neoplasms - genetics
  • Thyroid Neoplasms - physiopathology
  • Thyroid Neoplasms - surgery
  • Tumors
ispartof: The Lancet (British edition), 2016, Vol.388 (10061), p.2783-2795
description: Summary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.876714
LOCALfalse
PrimoNMBib
record
control
sourceidgale_opena
recordidTN_cdi_proquest_miscellaneous_1826692040
sourceformatXML
sourcesystemPC
galeidA519866467
sourcerecordidA519866467
originalsourceidFETCH-LOGICAL-c759t-3c4d46316c14cd2b326681a09ff684ee325c5b5f44daeacb46890b99bf9fe58c3
addsrcrecordideNqNk-9r1DAYx4so7jb1P1AE30ywM7-bIjjG8Mdg4Asn-C6kyZNbZq-5Ja1w_725q97djsONQkrL5_nkedJvi-IlRicYYfH-O8IMlaKi4hiLtxThipTiUTHBrGIlZ9XPx8VkjRwUhyndIISYQPxpcUAqwpCUfFK8uLpexODta6M7A_FZ8cTpNsHzv_ej4sfnT1fnX8vLb18uzs8uS1Pxui-pYZYJioXBzFjSUCKExBrVzgnJACjhhjfcMWY1aNMwIWvU1HXjagdcGnpUXIzeMIdO-whqHv1Mx4UK2ivbQa-CVVRIofI8eRxuDJOO1hW1BCFihLXEVRJAZtfx6JrHcDtA6tXMJwNtqzsIQ1JY5u5qghjK6Jsd9CYMscuTZio3SRHhckNNdQvKdy70UZulVJ1xXEshWD7U_1GsIhLVkvFMneyh8mVh5k3owPn8_o72QQXbO7zaU6C2jXuBbcO7LaAZku8g5SX56XWfpnpI6W6HD8C37XzETQwpRXDrT42RWkZZraKsljlV-WkVZSU2bc-HZgZ2XfUvuxn4sCM2vte9D12ez7f36k_Hasgx_-0hqmQ85H_A5jSaXtng7zV83DGY1nfe6PYXLCBtkqUSUWiULB1YrAyC_gF7Xx6_
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1846830258
display
typearticle
titleThyroid cancer
sourceAlma/SFX Local Collection
creatorCabanillas, Maria E, Dr ; McFadden, David G, MD ; Durante, Cosimo, MD
creatorcontribCabanillas, Maria E, Dr ; McFadden, David G, MD ; Durante, Cosimo, MD
descriptionSummary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(16)30172-6
3PMID: 27240885
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subjectCarcinoma, Neuroendocrine - diagnosis ; Carcinoma, Neuroendocrine - diagnostic imaging ; Carcinoma, Neuroendocrine - surgery ; Clinical trials ; Development and progression ; Diagnosis, Differential ; Disease-Free Survival ; Humans ; Internal Medicine ; Iodine ; Kinases ; Metastasis ; Mutation ; Severity of Illness Index ; Thyroid cancer ; Thyroid Neoplasms - diagnosis ; Thyroid Neoplasms - diagnostic imaging ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - physiopathology ; Thyroid Neoplasms - surgery ; Tumors
ispartofThe Lancet (British edition), 2016, Vol.388 (10061), p.2783-2795
rights
0Elsevier Ltd
12016 Elsevier Ltd
2Copyright © 2016 Elsevier Ltd. All rights reserved.
3COPYRIGHT 2016 Elsevier B.V.
4Copyright Elsevier Limited Dec 3, 2016
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-c759t-3c4d46316c14cd2b326681a09ff684ee325c5b5f44daeacb46890b99bf9fe58c3
citesFETCH-LOGICAL-c759t-3c4d46316c14cd2b326681a09ff684ee325c5b5f44daeacb46890b99bf9fe58c3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27240885$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Cabanillas, Maria E, Dr
1McFadden, David G, MD
2Durante, Cosimo, MD
title
0Thyroid cancer
1The Lancet (British edition)
addtitleLancet
descriptionSummary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
subject
0Carcinoma, Neuroendocrine - diagnosis
1Carcinoma, Neuroendocrine - diagnostic imaging
2Carcinoma, Neuroendocrine - surgery
3Clinical trials
4Development and progression
5Diagnosis, Differential
6Disease-Free Survival
7Humans
8Internal Medicine
9Iodine
10Kinases
11Metastasis
12Mutation
13Severity of Illness Index
14Thyroid cancer
15Thyroid Neoplasms - diagnosis
16Thyroid Neoplasms - diagnostic imaging
17Thyroid Neoplasms - genetics
18Thyroid Neoplasms - physiopathology
19Thyroid Neoplasms - surgery
20Tumors
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqNk-9r1DAYx4so7jb1P1AE30ywM7-bIjjG8Mdg4Asn-C6kyZNbZq-5Ja1w_725q97djsONQkrL5_nkedJvi-IlRicYYfH-O8IMlaKi4hiLtxThipTiUTHBrGIlZ9XPx8VkjRwUhyndIISYQPxpcUAqwpCUfFK8uLpexODta6M7A_FZ8cTpNsHzv_ej4sfnT1fnX8vLb18uzs8uS1Pxui-pYZYJioXBzFjSUCKExBrVzgnJACjhhjfcMWY1aNMwIWvU1HXjagdcGnpUXIzeMIdO-whqHv1Mx4UK2ivbQa-CVVRIofI8eRxuDJOO1hW1BCFihLXEVRJAZtfx6JrHcDtA6tXMJwNtqzsIQ1JY5u5qghjK6Jsd9CYMscuTZio3SRHhckNNdQvKdy70UZulVJ1xXEshWD7U_1GsIhLVkvFMneyh8mVh5k3owPn8_o72QQXbO7zaU6C2jXuBbcO7LaAZku8g5SX56XWfpnpI6W6HD8C37XzETQwpRXDrT42RWkZZraKsljlV-WkVZSU2bc-HZgZ2XfUvuxn4sCM2vte9D12ez7f36k_Hasgx_-0hqmQ85H_A5jSaXtng7zV83DGY1nfe6PYXLCBtkqUSUWiULB1YrAyC_gF7Xx6_
startdate2016
enddate2016
creator
0Cabanillas, Maria E, Dr
1McFadden, David G, MD
2Durante, Cosimo, MD
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
3Lancet Publishing Group
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BKMMT
9BSHEE
100TT
110TZ
120U~
133V.
147QL
157QP
167RV
177TK
187U7
197U9
207X7
217XB
2288A
2388C
2488E
2588G
2688I
278AF
288AO
298C1
308C2
318FE
328FH
338FI
348FJ
358FK
368G5
37ABUWG
38AN0
39ASE
40AZQEC
41BBNVY
42BEC
43BENPR
44BHPHI
45C1K
46DWQXO
47FPQ
48FYUFA
49GHDGH
50GNUQQ
51GUQSH
52H94
53HCIFZ
54K6X
55K9-
56K9.
57KB0
58KB~
59LK8
60M0R
61M0S
62M0T
63M1P
64M2M
65M2O
66M2P
67M7N
68M7P
69MBDVC
70NAPCQ
71PQEST
72PQQKQ
73PQUKI
74Q9U
75S0X
767X8
77BOBZL
78CLFQK
sort
creationdate2016
titleThyroid cancer
authorCabanillas, Maria E, Dr ; McFadden, David G, MD ; Durante, Cosimo, MD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c759t-3c4d46316c14cd2b326681a09ff684ee325c5b5f44daeacb46890b99bf9fe58c3
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Carcinoma, Neuroendocrine - diagnosis
1Carcinoma, Neuroendocrine - diagnostic imaging
2Carcinoma, Neuroendocrine - surgery
3Clinical trials
4Development and progression
5Diagnosis, Differential
6Disease-Free Survival
7Humans
8Internal Medicine
9Iodine
10Kinases
11Metastasis
12Mutation
13Severity of Illness Index
14Thyroid cancer
15Thyroid Neoplasms - diagnosis
16Thyroid Neoplasms - diagnostic imaging
17Thyroid Neoplasms - genetics
18Thyroid Neoplasms - physiopathology
19Thyroid Neoplasms - surgery
20Tumors
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Cabanillas, Maria E, Dr
1McFadden, David G, MD
2Durante, Cosimo, MD
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Gale General OneFile (A&I only)
8Academic OneFile (A&I only)
9News PRO
10Pharma and Biotech Premium PRO
11Global News & ABI/Inform Professional
12ProQuest Central (Corporate)
13Bacteriology Abstracts (Microbiology B)
14Calcium & Calcified Tissue Abstracts
15Nursing & Allied Health Database
16Neurosciences Abstracts
17Toxicology Abstracts
18Virology and AIDS Abstracts
19Health & Medical Collection
20ProQuest Central (purchase pre-March 2016)
21Biology Database (Alumni Edition)
22Healthcare Administration Database (Alumni)
23Medical Database (Alumni Edition)
24Psychology Database (Alumni)
25Science Database (Alumni Edition)
26STEM Database
27ProQuest Pharma Collection
28Public Health Database
29Lancet Titles
30ProQuest SciTech Collection
31ProQuest Natural Science Collection
32Hospital Premium Collection
33Hospital Premium Collection (Alumni Edition)
34ProQuest Central (Alumni) (purchase pre-March 2016)
35Research Library (Alumni Edition)
36ProQuest Central (Alumni Edition)
37British Nursing Database
38British Nursing Index
39ProQuest Central Essentials
40Biological Science Collection
41eLibrary
42ProQuest Central
43Natural Science Collection
44Environmental Sciences and Pollution Management
45ProQuest Central Korea
46British Nursing Index (BNI) (1985 to Present)
47Health Research Premium Collection
48Health Research Premium Collection (Alumni)
49ProQuest Central Student
50Research Library Prep
51AIDS and Cancer Research Abstracts
52SciTech Premium Collection
53British Nursing Index
54Consumer Health Database (Alumni Edition)
55ProQuest Health & Medical Complete (Alumni)
56Nursing & Allied Health Database (Alumni Edition)
57ProQuest Newsstand Professional
58ProQuest Biological Science Collection
59Consumer Health Database
60Health & Medical Collection (Alumni Edition)
61Healthcare Administration Database
62Medical Database
63Psychology Database
64Research Library
65Science Database
66Algology Mycology and Protozoology Abstracts (Microbiology C)
67Biological Science Database
68Research Library (Corporate)
69Nursing & Allied Health Premium
70ProQuest One Academic Eastern Edition
71ProQuest One Academic
72ProQuest One Academic UKI Edition
73ProQuest Central Basic
74SIRS Editorial
75MEDLINE - Academic
76OpenAIRE (Open Access)
77OpenAIRE
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Cabanillas, Maria E, Dr
1McFadden, David G, MD
2Durante, Cosimo, MD
formatjournal
genrearticle
ristypeJOUR
atitleThyroid cancer
jtitleThe Lancet (British edition)
addtitleLancet
date2016
risdate2016
volume388
issue10061
spage2783
epage2795
pages2783-2795
issn0140-6736
eissn1474-547X
codenLANCAO
abstractSummary Thyroid cancer is the fifth most common cancer in women in the USA, and an estimated over 62 000 new cases occurred in men and women in 2015. The incidence continues to rise worldwide. Differentiated thyroid cancer is the most frequent subtype of thyroid cancer and in most patients the standard treatment (surgery followed by either radioactive iodine or observation) is effective. Patients with other, more rare subtypes of thyroid cancer—medullary and anaplastic—are ideally treated by physicians with experience managing these malignancies. Targeted treatments that are approved for differentiated and medullary thyroid cancers have prolonged progression-free survival, but these drugs are not curative and therefore are reserved for patients with progressive or symptomatic disease.
copEngland
pubElsevier Ltd
pmid27240885
doi10.1016/S0140-6736(16)30172-6
oafree_for_read